Chronic Hepatitis C Study
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in Combination with Pegasys and Copegus for 12 to 24 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection
Protocol ID
Protocol Description
The purpose of this study is to learn if an experimental drug (RO5190591) can safely and successfully decrease the amount of hepatitis C virus in the body to a level where the virus cannot be measured. In addition, the study will look to see if the study drug works as well if taken every 12 hours compared to every 8 hours and whether it is better to take the drug for 12 weeks or 24 weeks. The study will evaluate RO5190591 in combination with currently FDA-approved treatments for chronic hepatitis C.
Eligibility Criteria
Patients diagnosed with chronic hepatitis C
Primary Investigator(s)
- David Bernstein, MD